Definitive Contract 75N91025C00046
Award Date
9/12/25
Potential Completion Date
9/11/26
Potential Value
$500K
Federal Agency
National Cancer Institute
Awardee
Gencyte Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Carlos, CA 94070, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $354,964 firm-fixed-price federal contract awarded by the National Cancer Institute to Gencyte Therapeutics Inc., a minority-owned small disadvantaged business. The contract is for Gencyte to develop a Synthetic Notch Receptor (SynNotch) controlled Precision Molecular Adaptor (PMA) system, named SynNotch PMA CAR, as a potential treatment for Juvenile Myelomonocytic Leukemia (JMML). The contract has a partial small business set-aside and is scheduled for completion by August 26, 2024.
This is a Small Business Innovation Research (SBIR) Concept Award issued by the National Cancer Institute, a civilian agency, for the development of therapeutic or preventative technologies to treat or prevent pediatric cancers and/or rare cancers. The $354,957.00 Firm Fixed Price contract was awarded to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, on September 5, 2025, with a completion date of September 4, 2026. The contract is set aside for total small business...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Transgenex Nanobiotech Inc. The contract is for the development of novel therapeutic agents that target cancer, under SBIR Topic 326. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $1,474,849.83 and an ultimate completion date of July 31, 2019. Transgenex Nanobiotech Inc. is a minority-owned, for-profit...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
This firm fixed price definitive contract was awarded by the National Institutes of Health National Cancer Institute to Senti Biosciences, Inc., a self-certified small disadvantaged business, for $1,999,993. The contract addresses Topic 414 from the fiscal year 2021 Small Business Innovation Research Program solicitation issued by the Department of Health and Human Services, which sought proposals for synthetic biology gene circuits for cancer therapy. The place of performance is South San...
<p>The National Cancer Institute (NCI) awarded a $196,192 Firm Fixed Price SBIR Phase I contract to Gencia Corporation, a minority-owned limited liability company. The contract aims to analyze the impact of the compound rhtFam on the mitochondrial activity and apoptotic potential of the MCF-7 breast cancer cell line. The contract was set aside for small businesses. No additional subcontractors were mentioned.</p>
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Pathcision Medicine, Inc., a minority-owned, woman-owned small business. The $354,941 firm-fixed-price contract is for the development of a novel delivery approach to transform the treatment and prevention of metastatic pancreatic cancer. The award is associated with a pre-solicitation opportunity that will focus on the development of innovative technologies for the...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...